Ligand Pharmaceuticals Incorporated
Engages in the development and commercialization of biopharmaceuticals as therapies to patients with unmet medical needs
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Ligand Pharmaceuticals' stock with a target price of $133.43, indicating potential growth.
Financial Health
Ligand Pharmaceuticals is earning strong profits and generating good cash flow, showing solid financial strength.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LGND
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Royalty Revenue Model
Recurring royalties and milestone payments can provide revenue visibility, though those streams depend on partner successes and are vulnerable to setbacks.
Proprietary Technology Platforms
Platforms such as Captisol and OmniAb can attract partners and diversify exposure, but they require ongoing investment and commercial uptake to deliver value.
Extensive Partnership Exposure
A wide partner base spreads risk across programmes and indications, yet regulatory delays or clinical failures at partners can still materially affect results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
